NCT01238783

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 5 Years
• Healthy volunteers: Not accepted

Summary

To assess safety and efficacy of AL-15469A 0.5% /AL-6515 0.3% Ophthalmic Suspension for treatment of bacterial conjunctivitis

Conditions

• Bacterial Conjunctivitis

Interventions

Type	Name	Description
DRUG	AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension	Topical ocular dosed 3 times per day for 3 days
DRUG	AL-15469A 0.5%	Topical ocular dosed 3 times per day for 3 days
DRUG	AL-6515 0.3%	Topical ocular dosed 3 times per day for 3 days
DRUG	Vehicle	Topical ocular dosed 3 times per day for 3 days

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-12-01
• First posted: 2010-11-11
• Last updated: 2011-12-01